Page 51 - Priority Review News Today

Positive phase 3 results from a trial studying fruquintinib, in patients with previously treated colorectal cancer (CRC) were announced by Hutchmed and Takeda on Friday (June 16).

Osaka: Takeda and HUTCHMED (China) Limited have announced that the European Medicines Agency (EMA) has validated and accepted for regulatory review the marketing authorization application (MAA) for...

— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) and ...

− Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) − Data support regulatory submissions in the U.S.,

— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S.,

Takeda TSE4502NYSETAK and HUTCHMED China Limited NasdaqAIMHCM HKEX13 HUTCHMED today announced that results of the Phase 3 FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer CRC were published in The Lancet.

OSAKA, Japan & CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Jun 15, 2023--

Paris , 21 October 2021 - Ipsen , a global specialty-driven biopharmaceutical group, publishes its sales performance for the third quarter of 2021 and the year to date. Sales... | June 16, 2023

An FDA committee voted unanimously that lecanemab-irmb (Leqembi) shows clinical benefit for the treatment of Alzheimer disease.

With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval...